~~13. A method for the treatment and/or prophylaxis of type-2 diabetes-associated pain, which comprises administering to the patient in need of such a treatment or prophylaxis a therapeutically effective amount of a sigma ligand as defined in any of claims 1 to 11.~~

~~14.~~13. A combination of at least one sigma ligand as defined in any of claims 1 to 11 and at least one further active substance for use in the treatment and/or prevention of type-2 diabetes-associated pain.